Ferran Fece de la Cruz
LightNews LightNews
banner
ferranfececruz.bsky.social
Ferran Fece de la Cruz
@ferranfececruz.bsky.social
390 followers 360 following 30 posts
Cancer researcher, Catalan, Instructor @MGHCancerCenter & @harvardmed.bsky.social #CorcoranLab
PhD in Malignant Diseases at @CeMM (Vienna) & @ludwigcancer.bsky.social (Oxford)
Posts Replies Media Videos
ferranfececruz.bsky.social
Pan-RAS inhibitor RMC-6236 aka Daraxonrasib in patients with RAS-mutant pancreatic adenocarcinoma 🤯🤯🤯 #GI25
dailynews.ascopubs.org/do/pan-ras-i...
January 25, 2025 at 10:46 PM
ferranfececruz.bsky.social
Phase 3 #BREAKWATER trial demonstrate a significantly improved response rate that was durable for first-line Encorafenib + Cetuximab + mFOLFOX6 vs. SOC in patients with BRAF V600E mCRC #crcsm #BRAF #GI25 @fightcrc.bsky.social
www.nature.com/articles/s41...
January 25, 2025 at 10:44 PM
ferranfececruz.bsky.social
Living the targeting #RAS era 🤯🤯🤯 #KRAS #G12C #G12D
www.cell.com/trends/cance...
December 30, 2024 at 3:51 PM
ferranfececruz.bsky.social
Great news fresh from #SABCS24 RLY-2608 (mutant selective PI3Kα inhibitor):
mPFS 9.2m (all patients)
mPFS 11.4m (for kinase domain mutants H1047R)
Clinical Benefit Rate 67%
#bcsm @breastcancernow.bsky.social
December 11, 2024 at 1:21 PM
ferranfececruz.bsky.social
Nivolumab plus Ipilimumab in Microsatellite-Instability–High Metastatic Colorectal Cancer 🤯🤯🤯 #crcsm #NEJM ⬇️⬇️⬇️
www.nejm.org/doi/full/10....
November 28, 2024 at 3:19 AM
ferranfececruz.bsky.social
go.bsky.app/JJcW2tg
November 23, 2024 at 11:34 PM
ferranfececruz.bsky.social
Great news for HR+/HER2- metastatic breast cancer patients!
#INAVO120 #bcsm @breastcancernow.bsky.social #NEJM
Next, mutant-selective PIK3CA inhibitors...
⬇️⬇️⬇️
www.nejm.org/doi/full/10....
November 20, 2024 at 11:22 PM